As President Trump touts his own executive orders to lower drug prices, the Medicare drug price negotiations begun during the Biden administration are continuing behind the scenes. Two companies – Novo Nordisk and Amgen – confirmed to NPR that they had received opening price offers from the government, kicking off bargaining that could last through October.
